BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension

• Status: Completed
• Trial end date: 2019-08-19
• Target enrollment: 0
• Participant gender: All

Summary

Patients who have completed the 12 weeks treatment of the PATENT-1 trial (study number 12934) will be asked to participate in this long term extension study with BAY63-2521.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Riociguat

Criteria

Inclusion Criteria:

• Patients who have completed 12 weeks of treatment in the double blind trial PATENT 1

Exclusion Criteria:

• Patients who have an ongoing serious adverse event from PATENT 1 that is assessed as related to BAY63-2521 are not allowed to participate in the extension trial.